69
Total Publications
7,664
Total Citations
Top Researchers
- Eva Muñoz 1,823 citations • 128 papers
- Ángel Burgos 233 citations • 10 papers
- A. Drozdowsky 10 citations • 1 papers
- Oscar Juan 10 citations • 1 papers
- Elisa Galvez 0 citations • 1 papers
Most Cited Papers
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial 2012 • 5,505 citations
- Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients 2018 • 270 citations
- Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial 2015 • 235 citations
- Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 2017 • 216 citations
- Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen 2006 • 204 citations
- Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer 2015 • 199 citations
- Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer 2017 • 181 citations
- BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors 2015 • 78 citations
- Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-Small Cell Lung Cancer Associated With Poor Prognosis 2018 • 77 citations
- BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale 2019 • 68 citations